Brian DeRubertis, MD, FACS

#VIVA24: Along with Lorenzo Patrone who is still in transit to Las Vegas, @sternvascular receives the 2024 VCA Award from @VIVAPhysicians. The accolade is given to young physician-leaders for vascular career advancement.

Register now: viva-foundation.org/register

The first patient has been successfully treated with our Esprit BTK Everolimus Eluting Resorbable Scaffold System, pioneering a new standard of care in BTK treatment. Thanks @PK_MountSinai and team for your commitment to your patients. Safety Info: bit.ly/3WAocNk

We followed a great morning with a wonderful afternoon watching the first Esprit BTK commercial case at Columbia performed by @sahilparikhmd @AbbottCardio #ProudtobeAbbott

Spending the morning with @derubertisMD observing the first commercial Esprit BTK case at Cornell is a great way to start the day. We are excited about what this therapy is bringing to patients. @AbbottCardio #ProudtobeAbbott

@UCIVascularSurg @Kabutey_MD @IsabellaKuoMD @SamuelChenMD @chauvascular @RMFujitaniMD @UCIrvineSurgery @UCIrvineSOM Congratulations!!!

We are excited to announce that we are ACGME accredited for our UCI/LBVA Vascular Fellowship! Thank you to everyone who has helped us achieve this monumental task!

Abbott Begins LIFE-BTK Trial to Evaluate Esprit BTK Drug-Eluting Resorbable Scaffold to Treat CLI | @AbbottNews evtoday.com/news/abbott-be…

Important time for patients suffering the threat of limb loss. Looking forward to the exciting work we have ahead of us in helping to evaluate this technology for our patients. @RamonVarcoeMD @sahilparikhmd